Paul Bird

Paul Bird

Auto-generated profile, based on publicly available information

Paul Bird

School of Clinical Medicine University of New South Wales Sydney New South Wales Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003
Verified
Journal Article
Closed access
MØMikkel Østergaard
Mikkel Østergaard
CPCharles Peterfy
Charles Peterfy
PCPhilip Conaghan
Philip Conaghan
FMFiona McQueen
Fiona McQueen
PBPaul Bird
Paul Bird
JEJohn Edmonds
John Edmonds

1 September 2011 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
PBPernille Bøyesen
Pernille Bøyesen
FMFIONA M. McQUEEN
FIONA M. McQUEEN
FGFrédérique Gandjbakhch
Frédérique Gandjbakhch
SLSiri Lillegraven
Siri Lillegraven
LCLaura Coates
Laura Coates
MØMikkel Østergaard
Mikkel Østergaard
Objective.The aim of this multireader exercise was to assess the reliability and sensitivity to change of the psoriatic arthritis magnetic resonance imaging score (PsAMRIS) in PsA patients followed for 1 year.Methods.MRI was acquired from 12 patients with PsA before initiation of treatment and after 12 months. MR images were scored according to PsAMRIS (for synovitis, tenosynovitis, periarticular inflammation, bone marrow edema, bone erosion, and bone proliferation) under standardized conditions, in unknown chronological order. Intraobserver/interobserver reliability was examined by intraclass correlation coefficients (ICC) and sensitivity to change by standardized response means (SRM).Results.The interobserver reliability of PsAMRIS was high for synovitis, tenosynovitis, periarticular inflammation, and bone edema status and change scores (interobserver ICC 0.87–0.97). The intraobserver reliability was moderate to high (ICC 0.60–0.98) for status and change scores, except for change in periarticular inflammation (ICC 0.33). PsAMRIS sensitivity to change was moderate for synovitis, tenosynovitis, and periarticular inflammation (SRM 0.5–0.8), while poor (SRM 0.1–0.3) for bone marrow edema, erosion, and bone proliferation. Rare occurrence and minimal change contributed to poor SRM and change-score ICC for bone parameters.Conclusion.This multireader exercise, performed under standardized conditions, confirmed PsAMRIS to have high interobserver and intraobserver reliability for hand PsA. Measures of inflammation were sensitive to change, implying that PsAMRIS may be a valuable tool for monitoring change in inflammation during PsA clinical trials.

5 September 2022 in Trials
Verified
Journal Article
Open access
PDF file
DGDafna D. Gladman
Dafna D. Gladman
PMPhilip J. Mease
Philip J. Mease
PBPaul Bird
Paul Bird
ESEnrique R. R. Soriano
Enrique R. R. Soriano
SCSoumya D. Chakravarty
Soumya D. Chakravarty
XBXenofon Baraliakos
Xenofon Baraliakos
Background: Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin (IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but have not shown efficacy in treating ankylosing spondylitis (AS), suggesting differences in axPsA processes and treatments. In a post hoc, pooled analysis of patients with investigator- and imaging-confirmed sacroiliitis in two phase 3, randomized, placebo-controlled studies (DISCOVER-1 and DISCOVER-2), patients treated with guselkumab, an IL-23p19 inhibitor, had greater axial symptom improvements compared with placebo. Confirmatory imaging at baseline was restricted to the sacroiliac (SI) joints, occurred prior to/at screening, and was locally read. Methods: The STAR study will prospectively assess efficacy outcomes in PsA patients with magnetic resonance imaging (MRI)-confirmed axial inflammation. Eligible, biologic-naïve patients with PsA (N = 405) for ≥ 6 months and active disease (≥ 3 swollen and ≥ 3 tender joints, C-reactive protein [CRP] ≥ 0.3 mg/dL) despite prior non-biologic disease-modifying antirheumatic drugs, apremilast, and/or nonsteroidal anti-inflammatory drugs will be randomized (1:1:1) to guselkumab every 4 weeks (Q4W); guselkumab at week (W) 0, W4, then every 8 weeks (Q8W); or placebo with crossover to guselkumab at W24, W28, then Q8W. Patients will have Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4, spinal pain component score (0–10 visual analog scale) ≥ 4, and screening MRI-confirmed axial involvement (positive spine and/or SI joints according to centrally read Spondyloarthritis Research Consortium of Canada [SPARCC] score ≥ 3 in ≥ 1 region). The primary endpoint is mean change from baseline in BASDAI at W24; multiplicity controlled secondary endpoints at W24 include AS Disease Activity Score employing CRP (ASDAS), Disease Activity Index for PsA (DAPSA), Health Assessment Questionnaire – Disability Index (HAQ-DI), Investigator’s Global Assessment of skin disease (IGA), and mean changes from baseline in MRI SI joint SPARCC scores. Centrally read MRIs of spine and SI joints (scored using SPARCC) will be obtained at W0, W24, and W52, with readers blinded to treatment group and timepoint. Treatment group comparisons will be performed using a Cochran-Mantel-Haenszel or chi-square test for binary endpoints and analysis of covariance, mixed model for repeated measures, or constrained longitudinal data analysis for continuous endpoints. Discussion: This study will evaluate the ability of guselkumab to reduce both axial symptoms and inflammation in patients with active PsA. Trial registration: This trial was registered at ClinicalTrials.gov, NCT04929210, on 18 June 2021. Protocol version: Version 1.0 dated 14 April 2021.

1 June 2003
Verified
Journal Article
Closed access
MLMarissa Lassere
Marissa Lassere
FMFiona McQueen
Fiona McQueen
MØMikkel Østergaard
Mikkel Østergaard
PCPhilip Conaghan
Philip Conaghan
RSRon Shnier
Ron Shnier
JEJohn Edmonds
John Edmonds

15 January 2013 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
PBPaul Bird
Paul Bird
HGHedley Griffiths
Hedley Griffiths
KTKathleen Tymms
Kathleen Tymms
DNDave Nicholls
Dave Nicholls
LRLynden Roberts
Lynden Roberts
GLGeoff Littlejohn
Geoff Littlejohn
Objective.: To assess the safety of treating patients with rheumatoid arthritis with a combination of methotrexate (MTX) and leflunomide (LEF) in comparison to MTX monotherapy, in clinical practice.Methods.: The Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis (SMILE) study was a multicenter, observational, cross-sectional, retrospective safety study. The study was conducted by the Optimising Patient Outcomes in Australian Rheumatology-Quality Use of Medicines Initiative (OPAL QUMI). Data were deidentified for patient, clinic, and clinician prior to collection from 13 participating rheumatology practices (25 rheumatologists). Comparative analysis of safety for the different treatments, primarily with regard to neutropenia and liver abnormalities, was performed.Results.: In total, 2975 patients were included in the study: 74% female, 26% male, mean age 62 years (SD 13.6). Distribution of therapy: MTX monotherapy 52.2%, LEF monotherapy 7.3%, MTX plus LEF 13.9%, and neither MTX nor LEF 26.6%. Comorbid liver disease was reported in 8.1% of patients. Liver function abnormalities were reported in 12% of the MTX monotherapy group, 16% of the LEF monotherapy group, 19% of the MTX-LEF combination group, and 14% of the group not taking either drug. Neutropenia was reported in 2.3% of the MTX monotherapy group, 5.5% of the LEF monotherapy group, 3.9% of the MTX-LEF combination group, and 4.2% of the group not taking either drug.Conclusion.: The combination of MTX and LEF was well tolerated, with adverse events comparable to those of monotherapy and the other nonbiologic disease-modifying antirheumatic drug treatment group.

1 April 2004
Verified
Journal Article
Closed access
JHJan Lucas Hoving
Jan Lucas Hoving
RBRachelle Buchbinder
Rachelle Buchbinder
SHStephen Hall
Stephen Hall
GLGary Lawler
Gary Lawler
PCPeter Coombs
Peter Coombs
DCDavid Connell
David Connell